AbbVie Updates 2026 Adjusted EPS Guidance After Q3 Expense
AbbVie Updates 2026 Adjusted EPS Guidance After Q3 Expense Moomoo
Covered in this story
What has happened since
- AbbVie is up 1.8% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on AbbVie
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Wells Fargo: $250 → $300 by Aug 2027 · Overweight via Investing.com
- Guggenheim: $244 → $288 by Aug 2027 · Buy via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Also covered by 1 other outlet
Dalsna Finance is currently tracking 48 stories mentioning AbbVie, the earliest published 29 Apr 2026.
Summary aggregated from Moomoo's public RSS feed. The full reporting belongs to Moomoo — please read it on their site.